Signaling new therapeutic opportunities: cytokines in prostate cancer
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2022.2108701
Abstract: ABSTRACT Introduction Despite FDA approval of sipuleucel-T in 2010, endeavors to use immune checkpoint inhibitors in unselected prostate cancer patients have not improved clinical outcomes. These efforts include studies with anti-PD1/PD-L1 and anti-CTLA-4 alone and… read more here.
Keywords: prostate cancer; signaling new; tumor microenvironment; cancer tumor ... See more keywords